Corcept Therapeutics

ISIN US2183521028

 | 

WKN 529882

Market cap (in EUR)
7,324 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 7,324 m
EPS, EUR 0.79
P/B ratio 13.6
P/E ratio 93.7
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 624 m
Net income, EUR 129 m
Profit margin 20.70%

What ETF is Corcept Therapeutics in?

There are 4 ETFs which contain Corcept Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Corcept Therapeutics is the iShares S&P SmallCap 600 UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares S&P SmallCap 600 UCITS ETF 0.47%
Equity
United States
Small Cap
1,737
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
485
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.12%
Equity
United States
Small Cap
178
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.